Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer-Reference-Cited by-同舟云学术

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

Published:2022-08 Issue:4 Volume:7 Page:100527
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Hotta K.,Hida T.,Nokihara H.,Morise M.,Kim Y.H.,Azuma K.,Seto T.,Takiguchi Y.,Nishio M.,Yoshioka H.,Kumagai T.,Watanabe S.,Goto K.,Satouchi M.,Kozuki T.,Shukuya T.,Nakagawa K.,Mitsudomi T.,Yamamoto N.,Asakawa T.,Yoshimoto T.,Takata S.,Tamura T.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference15 articles.

1. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

2. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update;Hanna;J Clin Oncol,2021

3. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial;Hida;Lancet,2017

4. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study;Gadgeel;Lancet Oncol,2014

5. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study;Seto;Lancet Oncol,2013

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study;JTO Clinical and Research Reports;2024-09

2. Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials;Cancers;2024-07-04

3. Efficacy analysis of ALK inhibitors for treating lung squamous carcinoma patients harboring ALK rearrangement;Journal of Thoracic Disease;2024-07

4. Rain Leaks Under the Trusted Tree;Journal of Thoracic Oncology;2024-07

5. The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma;Pathology - Research and Practice;2024-07